Senti Biosciences (SNTI) Revenue & Revenue Breakdown
Senti Biosciences Revenue Highlights
Latest Revenue (Y)
$2.56M
Main Segment (Y)
License
Senti Biosciences Revenue by Period
Senti Biosciences Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $2.56M | -40.25% |
2022-12-31 | $4.29M | 87.08% |
2021-12-31 | $2.29M | 481.47% |
2020-12-31 | $394.00K | 363.53% |
2019-12-31 | $85.00K | - |
Senti Biosciences Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | - | 100.00% |
2024-06-30 | - | 100.00% |
2024-03-31 | - | -100.00% |
2023-12-31 | $333.00K | 30.59% |
2023-09-30 | $255.00K | -72.79% |
2023-06-30 | $937.00K | -9.56% |
2023-03-31 | $1.04M | 1655.93% |
2022-12-31 | $59.00K | -96.66% |
2022-09-30 | $1.77M | 59.39% |
2022-06-30 | $1.11M | 29.74% |
2022-03-31 | $854.00K | 57.27% |
2021-12-31 | $543.00K | -41.36% |
2021-09-30 | $926.00K | 19.02% |
2021-06-30 | $778.00K | 980.56% |
2021-03-31 | $72.00K | 3500.00% |
2020-12-31 | $2.00K | - |
Senti Biosciences Revenue Breakdown
Senti Biosciences Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 22 |
---|---|
License | $800.00K |
Latest
Quarterly Revenue by Product
Product/Service | Jun 23 | Mar 23 |
---|---|---|
License | $200.00K | $400.00K |
Latest
Senti Biosciences Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
LIPO | Lipella Pharmaceuticals | $449.62M | $80.38M |
FHTX | Foghorn Therapeutics | $34.16M | $7.81M |
FENC | Fennec Pharmaceuticals | $21.64M | $6.97M |
SNTI | Senti Biosciences | $2.56M | - |
SABS | SAB Biotherapeutics | $2.24M | $263.14K |
BLCM | Bellicum Pharmaceuticals | $1.50M | $1.00M |
RAPT | RAPT Therapeutics | - | - |
CNTB | Connect Biopharma | - | - |
CING | Cingulate | - | - |
HILS | Tharimmune | - | - |
CVKD | Cadrenal Therapeutics | - | - |
NLTX | Neurogene | - | - |
MLYS | Mineralys Therapeutics | - | - |
MNPR | Monopar Therapeutics | - | - |
QNRX | Quoin Pharmaceuticals | - | - |
TYRA | Tyra Biosciences | - | - |
XLO | Xilio Therapeutics | - | $2.36M |